Interaction Guide · Research summary

Can I take Vitamin E with Pazopanib?

Review Vitamin E with Pazopanib: possible adverse effects, preparation details, evidence limits, and sources.

Prepared by Dr. Edward M.Kim, PharmD · Clinical Director, SupplementSafety editorial team

Research summary published · Prepared · Editorial update

The short answer

Vitamin E supplements deserve review while taking pazopanib, especially at high doses. The concern is precautionary; a direct increase in bleeding from this exact combination has not been measured.

What this answer covers

Oral pazopanib with vitamin E supplements; exact dose, preparation and other bleeding risks matter.

Supplement or preparation
Vitamin E
Medication ingredient
pazopanib

Check the exact treatment

This review concerns oral pazopanib tablets containing the hydrochloride salt, with doses expressed as pazopanib. It is used for specified advanced kidney cancer or soft-tissue sarcoma settings. Keep the prescribed fasting schedule and do not crush the tablets.

Why the combination needs review

Pazopanib can cause serious bleeding. High supplemental vitamin E can affect clotting; ordinary vitamin E in food is a different exposure. No exact-pair study establishes how much additional risk a particular product creates.

The human evidence is not uniform

A small randomized study in people taking warfarin found no significant INR change with vitamin E. It did not test this cancer medicine, and INR does not capture every bleeding mechanism. It therefore limits a blanket claim without establishing that high-dose supplements are safe for this combination.

Use symptoms and the treatment plan

Show the oncology team the product, dose and other medicines before starting it. Report unusual bruising or persistent bleeding; seek urgent care for major bleeding, black stools or vomiting blood. Do not rely on dose spacing or stop the cancer medicine yourself. Follow the blood-count and monitoring plan.

Evidence and practical considerations

Side effects & toxicity

The drug’s bleeding warning and supplement-specific guidance support conditional review while human counterevidence limits a universal causal claim.

Exact scope
Oral pazopanib with vitamin E supplements; exact dose, preparation and other bleeding risks matter. with RxNorm 714438 IN pazopanib. Current exact oral product: Pazopanib oral hydrochloride tablets. Salt/formulation named explicitly; no transfer to unrelated drugs or routes.
Medication form and route
Oral

What remains uncertain

  • No exact co-use bleeding-outcome trial. Supplement guidance and drug warning are a conditional bridge; proxy tests and different-drug null results retained.

Factors that may matter: Exact oral formulation and supplement preparation; Drug exposure versus clinical outcomes; Dose, duration and other medicines; Individual monitoring plan.

Research conclusion: supported with conditions · Evidence assessment: moderate

Read the supporting source summaries

Source 1: Current original prescribing information

dailymed.nlm.nih.gov · Source check Sep 10, 2026

Population: Patients prescribed the exact oral formulation.

Severe hepatotoxicity and bleeding warnings; CYP3A interaction precautions; avoid grapefruit products.

How this applies: RxNorm 714438 IN pazopanib. Current exact oral product: Pazopanib oral hydrochloride tablets. Salt/formulation named explicitly; no transfer to unrelated drugs or routes.

Exact current oral product source, not a clinical trial of every supplement. Formulation, dose, population and mechanism remain explicit.

Source 2: Original official nutrient guidance

ods.od.nih.gov · Source check Sep 10, 2026

Population: Supplement users; relevant clinical trials discussed.

High doses can affect clotting and raise bleeding concerns.

How this applies: Conditional supplement-risk bridge to drug bleeding warning.

Guidance not exact pazopanib co-use; no universal dose threshold or food-vitamin risk.

Source 3: Original clinical research

pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026

Population: 21 patients taking chronic warfarin.

No significant INR change detected.

How this applies: Exact reported preparation, population and endpoints; transfer to pazopanib explicitly limited.

Abstract-only small different-drug trial; INR is not every bleeding mechanism or a definitive bleeding-outcome safety trial.

Source 4: Medication terminology

rxnav.nlm.nih.gov · Source check Sep 10, 2026

Population: Terminology.

pazopanib is IN.

How this applies: Exact ingredient.

Not clinical evidence.

Research assessment: · Open full citations ↗

Review and change history

Publication status
Published research summary
Clinical review
Not yet recorded
DateUpdate
Research summary published
Article prepared
Sources checked and article drafted.

Article revision: c1f5b283dd39da7f

This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.

Full citations require verification. Reading this answer and the source summaries does not.

Taking other supplements or medications?

Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.

Open the interaction checker

Information, not medical advice. Do not change prescribed treatment based on this guide.